A drug acceptable complex for the treatment of disorders of quinoline-3-monooxygenation

摘要

Compounds and Pharmaceutical compositions are provided for treating patients suffering from certain diseases and disorders that respond to the KMO inhibition activity of these diseases including neurodegenerative Disorders such as Huntington's disease.Claim 1: a compound of formula (1) or its pharmaceutically acceptable Salt or prodrug, characterized in that: ru00b9 is optionally substituted heteroaryl; X - - - cru00b2ru00b3; Ru00b2 and ru00b3 are independently Hydrogen, optionally substituted amino, hydroxyl, Lower alkoxy,And optionally substituted Lower alkyl; R - C (o) o - ru2075; Hydrogen; and ru2076 and ru2077 are independently Hydrogen, halogen, alkoxy optionally substituted amino, hydroxyl, alkyl, optionally substituted Lower and Lower.